Livongo Health, Inc. Research and Development Expense
Livongo Health, Inc. reported Research and Development Expense of $15.81 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-08-10
- Livongo Health, Inc. research and development expense for the quarter ending 2020-06-30 was $15.81M, a 53.62% increase year-over-year.
- Livongo Health, Inc. research and development expense for the quarter ending 2020-03-31 was $14.00M, a 55.63% increase year-over-year.
- Livongo Health, Inc. research and development expense for the quarter ending 2019-12-31 was $12.76M, a 52.38% increase year-over-year.
- Livongo Health, Inc. research and development expense for the quarter ending 2019-09-30 was $17.79M, a 161.52% increase year-over-year.
- Livongo Health, Inc. research and development expense for fiscal 2019 was $49.84M, a 100.48% increase from fiscal 2018.
- Livongo Health, Inc. research and development expense for fiscal 2018 was $24.86M, a 106.69% increase from fiscal 2017.
- Livongo Health, Inc. research and development expense for fiscal 2017 was $12.03M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2020-06-30 | $15.81M 10-Q · filed 2020-08-10 | $29.81M 10-Q · filed 2020-08-10 | $42.57M derived: sum of 3 quarters · filed 2020-08-10 | $60.36M derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | $14.00M 10-Q · filed 2020-05-07 | $26.76M derived: sum of 2 quarters · filed 2020-05-07 | $44.55M derived: sum of 3 quarters · filed 2020-05-07 | $54.84M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-12-31 | $12.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | $30.56M derived: sum of 2 quarters · filed 2020-03-24 | $40.85M derived: sum of 3 quarters · filed 2020-08-10 | $49.84M 10-K · filed 2020-03-24 |
| 2019-09-30 | $17.79M 10-Q · filed 2019-11-08 | $28.09M derived: sum of 2 quarters · filed 2020-08-10 | $37.08M 10-Q · filed 2019-11-08 | $45.45M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-06-30 | $10.29M 10-Q · filed 2020-08-10 | $19.29M 10-Q · filed 2020-08-10 | $27.66M derived: sum of 3 quarters · filed 2020-08-10 | $34.47M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $8.99M 10-Q · filed 2020-05-07 | $17.37M derived: sum of 2 quarters · filed 2020-05-07 | $24.17M derived: sum of 3 quarters · filed 2020-05-07 | $29.71M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $8.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | $15.18M derived: sum of 2 quarters · filed 2020-03-24 | $20.71M derived: sum of 3 quarters · filed 2020-03-24 | $24.86M 10-K · filed 2020-03-24 |
| 2018-09-30 | $6.80M 10-Q · filed 2019-11-08 | $12.34M derived: sum of 2 quarters · filed 2019-11-08 | $16.48M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $5.53M 10-Q · filed 2019-09-05 | $9.68M 10-Q · filed 2019-09-05 | ||
| 2017-12-31 | $12.03M 10-K · filed 2020-03-24 |